Cost-Utility Analysis of Molecular Testing for Tuberculosis Diagnosis in Suspected Pulmonary Tuberculosis in Thailand

References

• Centers for Disease Control and Prevention. Core Curriculum on Tuberculosis: What the Clinician Should Know. Division of Tuberculosis Elimination; 2013.
   Google Scholar
• World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization; 2021.
   Google Scholar
• Kittikraisak W, Kingkaew P, Teerawattananon Y, et al. Health related quality of life among patients with tuberculosis and HIV in Thailand. PLoS One. 2012;7(1):e29775. doi:10.1371/journal.pone.0029775
   PubMed Web of Science ®Google Scholar
• World Health Organization. The End TB Strategy. Geneva: World Health Organization; 2015.
   Google Scholar
• Thailand operational plan to end tuberculosis 2017–2021. Division of Tuberculosis Department of Disease Control Ministry of Public Health Thailand; 2018. Available from: https://tbthailand.org/download/Manual/Thailand%20Operational%20Plan%20To%20End%20%20TB_2017_2021.pdf. Accessed January 20, 2022.
   Google Scholar
• Chadha VK, Anjinappa SM, Rade K, et al. Sensitivity and specificity of screening tools and smear microscopy in active tuberculosis case finding. Indian J Tuberc. 2019;66(1):99–104. doi:10.1016/j.ijtb.2018.05.015
   PubMedGoogle Scholar
• World Health Organization. National tuberculosis program guideline, Thailand. Division of Tuberculosis Department of Disease Control Ministry of Public Health Thailand; 2018.
   Google Scholar
• Virenfeldt J, Rudolf F, Camara C, et al. Treatment delay affects clinical severity of tuberculosis: a longitudinal cohort study. BMJ Open. 2014;4(6):e004818. doi:10.1136/bmjopen-2014-004818
   PubMed Web of Science ®Google Scholar
• World Health Organization. Policy Update: Xpert MTB/RIF Assay for the Diagnosis of Pulmonary and Extrapulmonary TB in Adults and Children. Geneva: World Health Organization; 2017.
   Google Scholar
• World Health Organization. The Use of Loop-Mediated Isothermal Amplification (TB-LAMP) for the Diagnosis of Pulmonary Tuberculosis. Geneva: World Health Organization; 2016.
   Google Scholar
• Menzies NA, Cohen T, Lin HH, et al. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med. 2012;9(11):e1001347. doi:10.1371/journal.pmed.1001347
   PubMed Web of Science ®Google Scholar
• World Health Organization. National tuberculosis control programme guideline Thailand 2018. Division of Tuberculosis Department of Disease Control Ministry of Public Health Thailand; 2018.
   Google Scholar
• NHSO annual report year 2020. Thailand: National Health Security Office, Ministry of Public Health; 2020. Available from: https://www.nhso.go.th/. Accessed August 25, 2021.
   Google Scholar
• Hao X, Lou H, Bai J, et al. Cost-effectiveness analysis of Xpert in detecting Mycobacterium tuberculosis: a systematic review. Int J Infect Dis. 2020;95:98–105. doi:10.1016/j.ijid.2020.03.078
   PubMed Web of Science ®Google Scholar
• Khumsri J, Hanvoravongchai P, Hiransuthikul N, et al. Cost-effectiveness analysis of Xpert MTB/RIF for multi-outcomes of patients with presumptive pulmonary tuberculosis in Thailand. Value Health Reg Issues. 2020;21:264–271. doi:10.1016/j.vhri.2019.09.010
   PubMedGoogle Scholar
• Schnippel K, Firnhaber C, Page-Shipp L, et al. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2018;22(8):918–925. doi:10.5588/ijtld.17.0869
   PubMed Web of Science ®Google Scholar
• Trade Policy and Strategy Office. Report for consumer price index of Thailand YEAR 2021 BASE YEAR 2019. Thailand: Ministry of Commerce; August 5, 2021. Available from: http://www.price.moc.go.th/price/cpi/index_new_all.asp. Accessed January 20, 2022.
   Google Scholar
• Guideline Development Working Group, the Medical Association of Thailand. Guideline for health technology assessment in Thailand updated edition: 2019; 2021.
   Google Scholar
• Chuchottaworn C, Roongruangpitayakul C. Drug susceptibility test and treatment outcome of recurrent pulmonary tuberculosis in Thailand. J Med Assoc Thai. 2017;100:733.
   Google Scholar
• Division of Tuberculosis Department of Disease Control Ministry of Public Health Thailand. Drug resistance surveillance (DRS) 5th. supranational Thailand reference laboratory. Available from: https://srlthailand.org/DRS5TH/Enrollmentreport.php#. Accessed July 29, 2021.
   Google Scholar
• National Tuberculosis Information Program (NTIP). Division of tuberculosis department of disease control ministry of public health Thailand; July 29, 2021. Available from: http://tbcmthailand.ddc.moph.go.th/UIForm/Tableau/TEST_tbcm.php. Accessed July 29, 2021.
   Google Scholar
• Shete PB, Farr K, Strnad L, et al. Diagnostic accuracy of TB-LAMP for pulmonary tuberculosis: a systematic review and meta-analysis. BMC Infect Dis. 2019;19(1):268. doi:10.1186/s12879-019-3881-y
   PubMed Web of Science ®Google Scholar
• Drug And Medical Supply Information Center Ministry of Public Health Thailand. The median drug prize. Available from: http://dmsic.moph.go.th/index/drugsearch/3. Accessed July 27, 2021.
   Google Scholar
• Thai Laboratory List (TLL). The comptroller general’s department, Thailand. Available from: https://mbdb.cgd.go.th/wel/searcheqpandmed.jsp#. Accessed July 27, 2021.
   Google Scholar
• Riewpaiboon A. Standard Cost Lists for Health Technology Assessment. Bangkok: Tana Press Co., Ltd.; 2011.
   Google Scholar
• Wongrot P. Economic burden of out-of-pocket payment for healthcare expenditures of tuberculosis patients in Thailand [dissertation]. Mahidol University; 2020.
   Google Scholar
• Drummond M, McGuire A. Economic Evaluation in Health Care: Merging Theory with Practice. Oxford University Press; 2001.
   Google Scholar
• Thavorncharoensap M, Teerawattananon Y, Natanant S, et al. Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter? Clinicoecon Outcomes Res. 2013;5:29–36. doi:10.2147/ceor.S38062
   PubMedGoogle Scholar
• Adelman M, Mcfarland D, Tsegaye M, et al. Cost-effectiveness of the World Health Organization-recommended algorithms for tuberculosis case finding at Ethiopian Human Immunodeficiency Virus (HIV) Clinics. Open Forum Infect Dis. 2016;3(suppl_1):549. doi:10.1093/ofid/ofw172.412
   Google Scholar
• Choi HW, Miele K, Dowdy D, et al. Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States. Int J Tuberc Lung Dis. 2013;17(10):1328–1335. doi:10.5588/ijtld.13.0095
   PubMed Web of Science ®Google Scholar
• Langley I, Lin -H-H, Egwaga S, et al. Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach. Lancet Glob Health. 2014;2(10):e581–e591. doi:10.1016/S2214-109X(14)70291-8
   PubMed Web of Science ®Google Scholar
• Pinto M, Steffen RE, Cobelens F, et al. Cost-effectiveness of the Xpert® MTB/RIF assay for tuberculosis diagnosis in Brazil. Int J Tuberc Lung Dis. 2016;20(5):611–618. doi:10.5588/ijtld.15.0455
   PubMed Web of Science ®Google Scholar
• Shah L, Rojas M, Mori O, et al. Cost-effectiveness of active case-finding of household contacts of pulmonary tuberculosis patients in a low HIV, tuberculosis-endemic urban area of Lima, Peru. Epidemiol Infect. 2017;145(6):1107–1117. doi:10.1017/s0950268816003186
   PubMed Web of Science ®Google Scholar
• Tesfaye A, Fiseha D, Assefa D, et al. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia. BMC Infect Dis. 2017;17(1):318. doi:10.1186/s12879-017-2417-6
   PubMed Web of Science ®Google Scholar
• Wikman-Jorgensen PE, Llenas-García J, Pérez-Porcuna TM, et al. Microscopic observation drug-susceptibility assay vs. Xpert® MTB/RIF for the diagnosis of tuberculosis in a rural African setting: a cost–utility analysis. Trop Med Int Health. 2017;22(6):734–743. doi:10.1111/tmi.12879
   PubMed Web of Science ®Google Scholar
• Winetsky DE, Negoescu DM, DeMarchis EH, et al. Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and Eastern Europe: a cost-effectiveness analysis. PLoS Med. 2012;9(11):e1001348. doi:10.1371/journal.pmed.1001348
   PubMed Web of Science ®Google Scholar
• You JHS, Lui G, Kam KM, et al. Cost-effectiveness analysis of the Xpert MTB/RIF assay for rapid diagnosis of suspected tuberculosis in an intermediate burden area. J Infect. 2015;70(4):409–414. doi:10.1016/j.jinf.2014.12.015
   PubMed Web of Science ®Google Scholar
• Zwerling AA, Sahu M, Ngwira LG, et al. Screening for tuberculosis among adults newly diagnosed with HIV in Sub-Saharan Africa: a cost-effectiveness analysis. J Acquir Immune Defic Syndr. 2015;70(1):83–90. doi:10.1097/QAI.0000000000000712
   PubMed Web of Science ®Google Scholar
• Vassall A, Siapka M, Foster N, et al. Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation. Lancet Glob Health. 2017;5(7):e710–e719. doi:10.1016/S2214-109X(17)30205-X
   PubMed Web of Science ®Google Scholar
• Cudahy PGT, Wilson D, Cohen T. Risk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study. BMC Infect Dis. 2020;20(1):789. doi:10.1186/s12879-020-05515-4
   PubMed Web of Science ®Google Scholar
• Apichaya T, Rapin P. Symptom experience of adverse drug reaction among male and female patients with newly diagnosed pulmonary tuberculosis in Thailand. Belitung Nurs J. 2021;7(3). doi:10.33546/bnj.1337
   Google Scholar
• Lugnér AK, Mylius SD, Wallinga J. Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic. Health Econ. 2010;19(5):518–531. doi:10.1002/hec.1485
   PubMed Web of Science ®Google Scholar
• World Health Organization. Systematic Screening for Active Tuberculosis: An Operation Guide. Geneva: World Health Organization; 2015.
   Google Scholar